AU2006316823A1 - F,G,H,I and K crystal forms of imatinib mesylate - Google Patents

F,G,H,I and K crystal forms of imatinib mesylate Download PDF

Info

Publication number
AU2006316823A1
AU2006316823A1 AU2006316823A AU2006316823A AU2006316823A1 AU 2006316823 A1 AU2006316823 A1 AU 2006316823A1 AU 2006316823 A AU2006316823 A AU 2006316823A AU 2006316823 A AU2006316823 A AU 2006316823A AU 2006316823 A1 AU2006316823 A1 AU 2006316823A1
Authority
AU
Australia
Prior art keywords
compound
formula
acid addition
addition salt
methanesulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006316823A
Other languages
English (en)
Inventor
Michael Mutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006316823A1 publication Critical patent/AU2006316823A1/en
Priority to AU2011201286A priority Critical patent/AU2011201286A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006316823A 2005-11-25 2006-11-23 F,G,H,I and K crystal forms of imatinib mesylate Abandoned AU2006316823A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201286A AU2011201286A1 (en) 2005-11-25 2011-03-22 F,G,H,I and K crystal forms of imatinib mesylate

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0524061.9 2005-11-25
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524062.7 2005-11-25
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001705P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28
US74001605P 2005-11-28 2005-11-28
US60/740,016 2005-11-28
US60/740,017 2005-11-28
US60/740,018 2005-11-28
PCT/EP2006/011240 WO2007059963A1 (en) 2005-11-25 2006-11-23 F,g,h,i and k crystal forms of imatinib mesylate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201286A Division AU2011201286A1 (en) 2005-11-25 2011-03-22 F,G,H,I and K crystal forms of imatinib mesylate

Publications (1)

Publication Number Publication Date
AU2006316823A1 true AU2006316823A1 (en) 2007-05-31

Family

ID=37847165

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006316823A Abandoned AU2006316823A1 (en) 2005-11-25 2006-11-23 F,G,H,I and K crystal forms of imatinib mesylate
AU2011201286A Ceased AU2011201286A1 (en) 2005-11-25 2011-03-22 F,G,H,I and K crystal forms of imatinib mesylate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011201286A Ceased AU2011201286A1 (en) 2005-11-25 2011-03-22 F,G,H,I and K crystal forms of imatinib mesylate

Country Status (13)

Country Link
US (6) US7893076B2 (enExample)
EP (3) EP1960380A1 (enExample)
JP (2) JP5844508B2 (enExample)
KR (4) KR20080078804A (enExample)
CN (1) CN102351842B (enExample)
AU (2) AU2006316823A1 (enExample)
BR (1) BRPI0618993A2 (enExample)
CA (3) CA2824307C (enExample)
EC (1) ECSP088473A (enExample)
MY (1) MY146403A (enExample)
NO (1) NO20082684L (enExample)
UY (1) UY29964A1 (enExample)
WO (1) WO2007059963A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
EP1960380A1 (en) * 2005-11-25 2008-08-27 Novartis AG F,g,h,i and k crystal forms of imatinib mesylate
US8414918B2 (en) 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
RU2365587C1 (ru) * 2008-02-22 2009-08-27 Закрытое Акционерное Общество "Фарм-Синтез" Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
US20120309767A1 (en) 2010-02-15 2012-12-06 Sharma Ashwani Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
US9221789B2 (en) 2012-06-22 2015-12-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
WO2015081175A1 (en) * 2013-11-26 2015-06-04 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
WO2004106326A1 (en) 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
CN1976709A (zh) 2004-06-04 2007-06-06 比奥尼斯生命科学公司 伊马替尼在治疗肝脏疾病和病毒感染中的用途
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
MX2008002541A (es) 2005-08-26 2008-03-14 Novartis Ag Formas de cristal delta y epsilon de mesilato de imatinib.
EP1960380A1 (en) * 2005-11-25 2008-08-27 Novartis AG F,g,h,i and k crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
CA2824307A1 (en) 2007-05-31
WO2007059963A1 (en) 2007-05-31
KR20080078804A (ko) 2008-08-28
NO20082684L (no) 2008-08-15
US20120015027A1 (en) 2012-01-19
CA2824301A1 (en) 2007-05-31
KR20130140909A (ko) 2013-12-24
CA2824307C (en) 2016-03-29
EP2578580A1 (en) 2013-04-10
US20110171301A1 (en) 2011-07-14
EP2546248A1 (en) 2013-01-16
KR20130141712A (ko) 2013-12-26
US20130224288A1 (en) 2013-08-29
CN102351842B (zh) 2014-07-23
US8846706B2 (en) 2014-09-30
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
US8592440B2 (en) 2013-11-26
UY29964A1 (es) 2007-06-29
CA2824301C (en) 2016-01-12
US20080268040A1 (en) 2008-10-30
US8198289B2 (en) 2012-06-12
US20120226038A1 (en) 2012-09-06
JP5844508B2 (ja) 2016-01-20
US20120015955A1 (en) 2012-01-19
MY146403A (en) 2012-08-15
JP2009517353A (ja) 2009-04-30
CA2628330A1 (en) 2007-05-31
KR20130137721A (ko) 2013-12-17
CN102351842A (zh) 2012-02-15
ECSP088473A (es) 2008-06-30
EP1960380A1 (en) 2008-08-27
CA2628330C (en) 2015-06-16
US8507515B2 (en) 2013-08-13
AU2011201286A1 (en) 2011-04-07
JP2014074067A (ja) 2014-04-24
BRPI0618993A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
AU2006283842B2 (en) Delta and epsilon crystal forms of imatinib mesylate
US8198289B2 (en) Crystal form H imatinib mesylate for pharmaceutical use
HK1177737A (en) Crystal form h of imatinib mesylate
MX2008006696A (en) F,g,h,i and k crystal forms of imatinib mesylate
CN101312960A (zh) 甲磺酸伊马替尼的f、g、h、i和k晶形

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted